Alfa-1-antitrypsinmangel

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Alfa-1-antitrypsinmangel. / de Vos, Jesper Dichmann; Hillberg, Ole; Perch, Michael; Jensen, Jens-Ulrik; Wilcke, Jon Torgny; Løkke, Anders.

In: Ugeskrift for Laeger, Vol. 183, No. 30, V02210150, 2021.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

de Vos, JD, Hillberg, O, Perch, M, Jensen, J-U, Wilcke, JT & Løkke, A 2021, 'Alfa-1-antitrypsinmangel', Ugeskrift for Laeger, vol. 183, no. 30, V02210150. <https://content.ugeskriftet.dk/sites/default/files/scientific_article_files/2021-07/v02210150_web.pdf>

APA

de Vos, J. D., Hillberg, O., Perch, M., Jensen, J-U., Wilcke, J. T., & Løkke, A. (2021). Alfa-1-antitrypsinmangel. Ugeskrift for Laeger, 183(30), [V02210150]. https://content.ugeskriftet.dk/sites/default/files/scientific_article_files/2021-07/v02210150_web.pdf

Vancouver

de Vos JD, Hillberg O, Perch M, Jensen J-U, Wilcke JT, Løkke A. Alfa-1-antitrypsinmangel. Ugeskrift for Laeger. 2021;183(30). V02210150.

Author

de Vos, Jesper Dichmann ; Hillberg, Ole ; Perch, Michael ; Jensen, Jens-Ulrik ; Wilcke, Jon Torgny ; Løkke, Anders. / Alfa-1-antitrypsinmangel. In: Ugeskrift for Laeger. 2021 ; Vol. 183, No. 30.

Bibtex

@article{f94f2d4344244dd1bb59032a6813e34c,
title = "Alfa-1-antitrypsinmangel",
abstract = "The subject of this review is alpha-1-antitrypsin deficiency (A1AD), which is a rare hereditary disease with great impact in adults, especially smokers, quality of life and longevity. Early diagnosis is crucial for treatment outcome. The primary care physician should refer patients younger than 50-years-old with COPD or emphysema, familiar accumulation of A1AD or liver cirrhosis of unknown cause. Most important treatment is smoking cessation, pulmonary rehabilitation and inhaled medication according to current guidelines. Substitution treatment with alpha-1-antitrypsin is now an option after its approval by the Danish medical council in January 2020.",
keywords = "Adult, Humans, Liver Cirrhosis, Middle Aged, Pulmonary Emphysema/etiology, Quality of Life, Smoking Cessation, alpha 1-Antitrypsin Deficiency/complications",
author = "{de Vos}, {Jesper Dichmann} and Ole Hillberg and Michael Perch and Jens-Ulrik Jensen and Wilcke, {Jon Torgny} and Anders L{\o}kke",
year = "2021",
language = "Dansk",
volume = "183",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "30",

}

RIS

TY - JOUR

T1 - Alfa-1-antitrypsinmangel

AU - de Vos, Jesper Dichmann

AU - Hillberg, Ole

AU - Perch, Michael

AU - Jensen, Jens-Ulrik

AU - Wilcke, Jon Torgny

AU - Løkke, Anders

PY - 2021

Y1 - 2021

N2 - The subject of this review is alpha-1-antitrypsin deficiency (A1AD), which is a rare hereditary disease with great impact in adults, especially smokers, quality of life and longevity. Early diagnosis is crucial for treatment outcome. The primary care physician should refer patients younger than 50-years-old with COPD or emphysema, familiar accumulation of A1AD or liver cirrhosis of unknown cause. Most important treatment is smoking cessation, pulmonary rehabilitation and inhaled medication according to current guidelines. Substitution treatment with alpha-1-antitrypsin is now an option after its approval by the Danish medical council in January 2020.

AB - The subject of this review is alpha-1-antitrypsin deficiency (A1AD), which is a rare hereditary disease with great impact in adults, especially smokers, quality of life and longevity. Early diagnosis is crucial for treatment outcome. The primary care physician should refer patients younger than 50-years-old with COPD or emphysema, familiar accumulation of A1AD or liver cirrhosis of unknown cause. Most important treatment is smoking cessation, pulmonary rehabilitation and inhaled medication according to current guidelines. Substitution treatment with alpha-1-antitrypsin is now an option after its approval by the Danish medical council in January 2020.

KW - Adult

KW - Humans

KW - Liver Cirrhosis

KW - Middle Aged

KW - Pulmonary Emphysema/etiology

KW - Quality of Life

KW - Smoking Cessation

KW - alpha 1-Antitrypsin Deficiency/complications

M3 - Tidsskriftartikel

C2 - 34356027

VL - 183

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 30

M1 - V02210150

ER -

ID: 288056330